Clinica Baviera (XMAD:CBAV) YoY EBITDA Growth: 23.26% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XMAD:CBAV Clinica Baviera SA XMAD:CBAV
100 GF Score
Price €58.80
GF Value €44.43
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Clinica Baviera YoY EBITDA Growth?

Clinica Baviera XMAD:CBAV +0.68% 100 YoY EBITDA Growth is 23.26% as of Jun. 2026. GuruFocus rates XMAD:CBAV with a GF Score™ of 100/100 and a GF Value™ of €44.43 (Significantly Overvalued). The stock has 5 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Clinica Baviera's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 23.26%.

Clinica Baviera's EBITDA per Share for the three months ended in Jun. 2026 was €1.59.

Clinica Baviera YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Clinica Baviera's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clinica Baviera YoY EBITDA Growth Chart

Clinica Baviera Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 55.99 4.94 19.79 18.39 10.41

Clinica Baviera Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 35.81 7.64 9.08 23.26
XMAD:CBAV
100GF Score
Clinica Baviera SA XMAD:CBAV
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clinica Baviera YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Clinica Baviera's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(5.388-4.88)/ | 4.88 |
=10.41 %

Clinica Baviera's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(1.59-1.29)/ | 1.29 |
=23.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 23.26% mean?
Clinica Baviera (XMAD:CBAV) has a YoY EBITDA Growth of 23.26% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Clinica Baviera and its competitors.
Is Clinica Baviera's YoY EBITDA Growth too high?
Clinica Baviera's current YoY EBITDA Growth is 23.26%. Overall, Clinica Baviera has a GF Score™ of 100/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clinica Baviera's YoY EBITDA Growth compare to TMO and DHR?
Clinica Baviera's YoY EBITDA Growth of 23.26% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Diagnostics & Research company?
A good YoY EBITDA Growth depends on the Medical Diagnostics & Research industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Clinica Baviera and its competitors. Clinica Baviera's current YoY EBITDA Growth is 23.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinica Baviera stock overvalued right now?
Based on GuruFocus' analysis, Clinica Baviera (XMAD:CBAV) is currently considered Significantly Overvalued. The stock's GF Value™ is €44.43, compared to a current price of €58.80 — trading 32.3% above its estimated fair value. The current YoY EBITDA Growth is 23.26%. Clinica Baviera's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Clinica Baviera (XMAD:CBAV), the current YoY EBITDA Growth is 23.26% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clinica Baviera (XMAD:CBAV) Overvalued in 2026?

Based on GuruFocus' analysis, Clinica Baviera stock appears to be overvalued. The current stock price of €58.80 is trading 32.3% above its estimated GF Value™ of €44.43. GuruFocus considers Clinica Baviera to be Significantly Overvalued.

Key valuation signals for XMAD:CBAV:

  • YoY EBITDA Growth: 23.26%
  • GF Value™: €44.43 vs. price of €58.80 (32.3% above fair value)
  • GF Score™: 100/100 with 5 warning signs

No single metric tells the full story. See the XMAD:CBAV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Clinica Baviera Business Description

Other Exchanges 0GWJ:UKD9Z:Germany
Address Paseo de la Castellana 20, Madrid, ESP, 28046
Clinica Baviera SA operates ophthalmological clinics. It is involved in the diagnosis, treatment, and monitoring of various types of ophthalmological disorders. It offers diagnosis and treatment for various eye problems such as long-sightedness, short-sightedness, astigmatism, cataracts and eye strain.
100GF Score

Get the complete analysis for XMAD:CBAV

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€58.80
Price
€44.43
GF Value